Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Avalo Therapeutics (AVTX) Net Margin (2016 - 2025)

Avalo Therapeutics' Net Margin history spans 11 years, with the latest figure at 23254.24% for Q4 2025.

  • For Q4 2025, Net Margin fell 484851.0% year-over-year to 23254.24%; the TTM value through Dec 2025 reached 132642.37%, down 12467661.0%, while the annual FY2025 figure was 132642.37%, 12467661.0% down from the prior year.
  • Net Margin reached 23254.24% in Q4 2025 per AVTX's latest filing, down from 18405.73% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 9251.81% in Q3 2024 to a low of 23254.24% in Q4 2025.
  • Average Net Margin over 4 years is 3588.02%, with a median of 1274.18% recorded in 2023.
  • The largest YoY upside for Net Margin was 1146706bps in 2024 against a maximum downside of -1697526bps in 2024.
  • A 4-year view of Net Margin shows it stood at 29.68% in 2021, then plummeted by -4720bps to 1430.47% in 2023, then crashed by -1187bps to 18405.73% in 2024, then decreased by -26bps to 23254.24% in 2025.
  • Per Business Quant, the three most recent readings for AVTX's Net Margin are 23254.24% (Q4 2025), 18405.73% (Q4 2024), and 9251.81% (Q3 2024).